Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 versus TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 versus TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER.
AMINOSYN-HBC 7% vs TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HBC 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, supporting anabolism and tissue repair in patients with high metabolic stress.
Provides exogenous amino acids and dextrose to meet caloric and protein requirements in patients who cannot tolerate enteral nutrition. Amino acids are used for protein synthesis and as substrates for gluconeogenesis and other metabolic pathways.
Intravenous infusion; typical adult dose: 1.0-1.5 g/kg/day of amino acids, administered as a continuous infusion over 12-24 hours.
Intravenous infusion: 500 mL to 1000 mL over 24 hours, titrated to provide 2.75% amino acids and 20% dextrose as part of parenteral nutrition. Rate based on glucose tolerance and metabolic needs.
None Documented
None Documented
Not applicable; amino acids are continuously metabolized and recycled. For individual amino acids, terminal half-life ranges from minutes to hours depending on metabolic demand.
Amino acids: not applicable (endogenous metabolites). Dextrose: <15 minutes; clinical context: continuous infusion required to maintain glucose homeostasis.
Renal: >90% as amino acids and metabolites; minimal biliary/fecal elimination.
Amino acids and dextrose are metabolized; excess nitrogen is excreted primarily as urea in urine. Dextrose is metabolized to CO2 and water. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution